Bruno Fant

Bruno Fant

Company: myNEO Therapeutics

Job title: Chief Technology Officer


Bringing Novel Class of Vaccine Targets into Development – Camyopeptides Derived from Tumour-Specific IncRNAs 9:00 am

Results from the profiling of over 1500+ tumour biopts and neoantigen landscapes First glance at immunological responses revealing first-in-class potential of shared tumor targets Designing the mRNA-LNP cancer vaccineRead more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.